Target Population Selection: Biomarker profile – applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS <10%) or zero identifies patients
Keynote presentation at leading head and neck cancer conference will include new findings from CEL-SCI’s landmark Phase 3 study, the largest in the world for its indication
CEL-SCI’s patient selection method is a
Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer
The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatment
Study concludes
Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory Registration
Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America
The 212-patient confirmatory study is powered at approximately 97% to confirm a previously
Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration
Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of
U.S. Confirmatory Registration Study expected to begin Summer 2026
Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price
Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030
Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies
Strategic
On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026
Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia
50%/50%
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an
50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation
Amarox to act as the local regulatory representative and lead all communications with the
